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Abstract Formerly, the disastrous cluster of neurologic
deficits and associated neurogenic problems in patients
with myelomeningocele (MMC) was generally thought to
solely result from the primary malformation, i.e., failure of
neurulation. Today, however, there is no doubt that a
dimensional additional pathogenic mechanism exists. Most
likely, it contributes much more to loss of neurologic
function than non-neurulation does. Today, there is a large
body of compelling experimental and clinical evidence
confirming that the exposed part of the non-neurulated
spinal cord is progressively destroyed during gestation,
particularly so in the third trimester. These considerations
gave rise to the two-hit-pathogenesis of MMC with non-
neurulation being the first and consecutive in utero
acquired neural tissue destruction being the second hit.
This novel pathophysiologic understanding has obviously
triggered the question whether the serious and irreversible
functional loss caused by the second hit could not be pre-
vented or, at least, significantly alleviated by timely pro-
tecting the exposed spinal cord segments, i.e., by early in
utero repair of the MMC lesion. Based on this intriguing
hypothesis and the above-mentioned data, human fetal
surgery for MMC was born in the late nineties of the last
century and has made its way to become a novel standard
of care, particularly after the so-called ‘‘MOMS Trial’’.
This trial, published in the New England Journal of Med-
icine, has indisputably shown that overall, open prenatal
repair is distinctly better than postnatal care alone. Finally,
a number of important other topics deserve being men-
tioned, including the necessity to work on the up till now
immature endoscopic fetal repair technique and the need
for concentration of these extremely challenging cases to a
small number of really qualified fetal surgery centers
worldwide. In conclusion, despite the fact that in utero
repair of MMC is not a complete cure and not free of risk
for both mother and fetus, current data clearly demonstrate
that open fetal–maternal surgery is to be recommended as
novel standard of care when pregnancy is to be continued
and when respective criteria for the intervention before
birth are met. Undoubtedly, it is imperative to inform
expecting mothers about the option of prenatal surgery
once their fetus is diagnosed with open spina bifida.
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Introduction
The first surgeon to ever operate on a human being in utero
was Michael R. Harrison from San Francisco, USA, who
performed an open vesicostomy in a fetus with posterior
urethral valves in 1981 [1].
Even though fetal surgery has made enormous progress
over the last 30 years, there are still only few conditions
justifying a surgical intervention before birth. The classical
indications are open spina bifida (open repair), congenital
pulmonary airway malformations (open resection), sacro-
coccygeal teratomas (open resection), and congenital dia-
phragmatic hernia (endoscopic tracheal plugging) [2–8].
The goal of this article is to review all pertinent aspects
with regard to fetal surgery for spina bifida aperta, or
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myelomeningocele (MMC) which, by far, represents the
most frequent and thus also the clinically most relevant
indication for prenatal surgery today.
A radical change of paradigm: secondary, i.e., in utero
acquired, CNS pathology plays a crucial
pathophysiological role
Until the end of the last century, MMC (spina bifida cystica
aperta) and the sister malformation termed myeloschisis
(the non-cystic variant) were thought to be the result of
non-neurulation, typically occurring at the end of the first
gestational month in the lumbosacral area of the spinal
cord. Also, the most serious neurological and develop-
mental problems including the rather complex Chiari II
malformation, hydrocephalus, paraparesis or paraplegia,
neuropathic voiding problems of bladder and rectum, as
well as multiple orthopedic pathologies, and also endocri-
nologic, sexual, intellectual, and psychosocial abnormali-
ties were basically attributed to the primary malformation.
Of note, at term, all neurologic deficits are irreversible and
there is no real cure for any of the above-mentioned con-
ditions. The patients suffer from a lifelong cluster of
handicaps and depend on corrective, rehabilitative, or
palliative therapeutic measures.
The first histological descriptions of postnatal MMC
lesions showing signs of mechanical trauma, neural tissue
degeneration, and massive inflammation were published
about 60 years ago by Patten [9] and Cameron [10]. They
suggested that this marked spinal cord damage was most
likely caused by labor and a harmful passage through the
narrow birth canal that crushed and abraded the openly
exposed and thus extremely vulnerable neural tissue.
Interestingly, there was no explicit mentioning that these
apparently late gestational and secondary phenomena could
be key factors for the neurological deficit. Also, there was
no speculation that during the prenatal development of
MMC there might be an early phase of relatively good or
even near normal spinal cord function despite partial non-
neurulation.
Only when fetal surgery was launched by Harrison [1], a
specific understanding was gradually established that con-
genital malformations do in fact have a natural prenatal
history during which dramatic and clinically relevant, mostly
negative, processes occur. With regard to open spina bifida,
the in utero natural history was studied extensively over the
past few decades and convincing experimental as well as
clinical evidence led to the ‘‘two-hit-pathogenesis’’ for this
devastating malformation. Hence, the first hit is non-neuru-
lation and the second is in utero acquired spinal cord
destruction. The thrilling story of how this novel concept was
elaborated is narrated below.
The contemporary key figures were Johns Hopkins
pathologist Grover M. Hutchins and a number of partner
researchers including Heffez, Jordan, Blakemore, and
Meuli who analyzed the MMC lesions of a few dozens of
human fetuses with spina bifida aperta in detail [11–16].
Taken together, this research line has, for the first time,
provided an accurate anatomical description of the typical
MMC lesion that is graphically depicted in Fig. 1.
Hereby, one observation is of particular clinical rele-
vance. Although the spinal cord tissue within the lesion is
always non-neurulated, the characteristic histologic hall-
marks of the cord as well as the sensorimotor projections
to and from it were present on a regular basis. Further-
more, the exposed neural tissue was histologically intact
in early gestation, but showed progressive damage
(abrasion, erosion, disruption, hemorrhage, inflammation,
degeneration) and finally even disappeared in some
specimens completely in late gestation [12, 16]. Since
these features were found in all cases alike, it was tenable
to derive the ‘‘two-hit-pathogenesis’’ from them with the
primary malformation (non-neurulation) representing the
first, and in utero acquired damage (trauma, inflamma-
tion, degeneration) representing the second hit. This quite
revolutionary pathophysiological understanding instantly
fuelled the intriguing idea that timely in utero protective
coverage of a MMC lesion could stop the otherwise
progressing spinal cord destruction and thus salvage
neurologic function at birth. Perhaps, following prenatal
repair, the power of fetal wound healing and a good deal
of neural plasticity could eventually lead to recuperation
of function previously lost.
There is compelling experimental evidence, in par-
ticular the one generated by Micheida (monkey) [17],
Heffez (rat and pig) [13, 14], Jennings (rabbit) [18] and
Meuli (sheep) [19–21] to demonstrate that surgically
created lesions mimicking as closely as possible the
human open spina bifida lesion in experimental fetuses
led to characteristic MMC lesions and loss of function
at birth. The two studies mimicking best the natural in
utero course of human MMC and also the marked
functional benefit induced by in utero repair of such
lesions are the ones published by Meuli/Adzick in
Nature Medicine [19] and by Stiefel/Meuli in The
Journal of Neurosurgery [22]. The Nature Medicine
article essentially demonstrates in a fetal sheep model
that a surgically created human-like spina bifida defect
with exposure of the normal spinal cord to the amniotic
fluid, performed at midgestation, developed into an
almost classical human-like cystic MMC lesion at birth.
And, even more importantly, the newborn lambs were
paraplegic and incontinent. These dynamics prove that
direct and prolonged exposure of normal spinal cord
tissue to the amniotic cavity leads to dramatic loss of
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function. The same article also reports on successful in
utero repair of developing ‘‘mini’’-MMC. Fetuses in
which a midgestational MMC was created and then
repaired in utero using a distally pedicled latissimus
dorsi flap [23] 4 weeks thereafter were neurologically
normal at birth. These results prove that timely in utero
coverage of exposed spinal cord tissue is protective and
spares function [19]. The Journal of Neurosurgery
article delivers a sort of ultimate proof for the cor-
rectness of the two-hit-pathogenesis by looking at the
natural in utero and postnatal course in a genetic mouse
model of MMC. Early gestational MMC fetuses dem-
onstrated sensorimotor function that was identical with
that of healthy control fetuses, and, anatomically, they
showed normal sensory and motor projections to and
from the non-neurulated but otherwise intact spinal
cord. Neonatal pups, however, were paralyzed and
histologically, there were no or only minimal residues
of the formerly exposed neural tissue [22]. This
‘‘experiment of nature’’ confirms that spinal cord
function is present in early gestation and is progres-
sively diminished during later stages of gestation until
an almost complete and irreversible loss at birth. A
number of experimental studies were carried out and
basically corroborated the conclusions drawn from the
above studies [24–29]. An important piece of under-
standing was added by Bouchard and Paek who inde-
pendently produced evidence (using the fetal sheep
model originally described by Meuli et al.) that a kind
of ‘‘Chiari-malformation’’ with hindbrain herniation and
hydrocephalus formation can be induced when a cere-
brospinal fluid leak is created within the lumbar MMC
lesion and that this process is reversible upon in utero
coverage of the lesion [30, 31].
Taken together, the above-quoted evidence has paved
the way for fetal surgery to be commenced in human
fetuses suffering from this ruinous malformation.
Diagnostic workup and prenatal counseling
An open spina bifida is mainly detected by ultrasound first
(it can be seen as early as about 16 weeks of gestation) and
then confirmed by a fetal–maternal MRI. For a fetus and
his mother to qualify for maternal–fetal surgery, the mother
must be healthy (there is a long list of exclusion criteria!),
the fetus must not suffer from other pathologies than the
MMC complex, and the intervention must be performed
between 20 and 26 weeks of gestation. Of course, a written
Fig. 1 Graphical cross section through the center of the classical
cystic human MMC lesion: the non-neurulated spinal cord resides on
top of a cystic formation that is dorsally formed by open pia and
ventrally by open dura. The neural tissue is directly exposed to the
amniotic fluid during gestation, or to air post birth. The abnormally
shaped arachnoid space contains cerebrospinal fluid. The pia mater
merges bilaterally into the epidermis and superficial dermis, the dura
mater merges into the deep dermis of the normal skin that surrounds
the lesion. In case of the so-called myeloschisis, the arachnoidal
space is collapsed, and the non-neurulated spinal cord rests in the
gutter formed by the vertebral body and the remnants of the vertebral
arches. (Georg Thieme Verlag KG)
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informed consent must be obtained following a non-
directive prenatal counseling.
The first studies of human fetal surgery for MMC
produce encouraging results and set the stage
for the MOMS Trial (Management
of Myelomeningocele Study)
The pre-MOMS era was essentially coined by the work of
the three American centers who later joined forces to
carry out the MOMS Trial. In 1997, Bruner from Van-
derbilt University reported on the very first case of a (non
successful) endoscopic human fetal MMC repair [32]. In
1998, Adzick, from the Children’s Hospital of Philadel-
phia (CHOP), performed the first (successful) open repair
(Fig. 2) [33]. A year later, Bruner and Sutton (CHOP)
published sister papers in the same JAMA issue reporting
that fetal MMC repair reversed hindbrain herniation
(Fig. 3) in almost all fetuses and thereby reduced the need
for shunt placement by about 50 % [34, 35]. The Phila-
delphia group also produced a remarkable sequence of
follow-up studies essentially confirming that hindbrain
herniation is reversible and that the shunt rate drops
dramatically [36, 37]. Moreover, the CHOP cohort
exhibited a favorable evolution with regard to head size
[38], brainstem function [39], motor function of the legs
[40], and several neurodevelopmental parameters [41,
42]. On the negative side of the spectrum, some patients
had neurological worsening due to retethering of the
spinal cord at the repair site [43]. The Vanderbuilt group
studied bladder and bowel function 7–10 years after in
utero repair and did not find significant differences from
patients with postnatal care [44]. Interestingly, there is a
study showing a global defect in smooth and skeletal
muscle as well as nerve density in the lower genitourinary
and gastrointestinal tract of male human fetuses with
MMC at 20 weeks of gestation [45]. A study by the
Vanderbuilt group revealed that fetal repair beyond the
26th gestational week is not as effective anymore (Fig. 4).
This is one reason why the window of opportunity for
fetal repair, i.e., from 20 to 26 gestational weeks, closes at
this timepoint [46]. Importantly, the CHOP group has
shown that women do not experience a loss of repro-
ductive capacity due to maternal–fetal surgery nor do they
have higher hysterotomy risks than those present after
conventional C-sections [47, 48]. In summary, the
ensemble of all clinical data fostered the conception of
what finally turned out to be the most influential milestone
study ever conducted in the history of fetal surgery: The
MOMS Trial, a prospective, randomized, multicenter
clinical trial to compare 100 fetal with 100 postnatal
MMC repairs.
The MOMS trial makes open fetal surgery a novel
treatment standard
The trial started in 2003 and was prematurely stopped by
the data and safety monitoring committee in 2010 after
inclusion of 183 of the planned 200 eligible women.
Because of significantly better results in the fetal therapy
group, further randomization was considered unjustifiable
and unethical. The key findings with regard to the primary
and some of the most relevant secondary outcomes are
listed and commented on below.
The prenatal surgery group compared favorably with the
postnatal surgery group in terms of both primary outcomes,
Fig. 2 Open fetal surgery: a the cystic sac (zona epithelioserosa;
between dotted lines) is being resected. In the center of the picture lies
the openly exposed, non-neurulated, but macroscopically undamaged
spinal cord. b Bilateral myofascial (dotted line) flaps are being sewn
over the cord (this is one of our own cases)
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i.e., fetal or neonatal death and shunt placement at
12 months of age, as well as mental development and
motor function at 30 months of age (highly significant
statistics!).
Also, the prenatal surgery group showed significantly
better secondary outcomes with regard to hindbrain her-
niation, lower extremity motor function, and chances of
independent walking.
However, the risks of spontaneous rupture of mem-
branes, persistent oligohydramnios, spontaneous labor, and
preterm delivery were significantly higher in the prenatal
than in the postnatal surgery group.
Maternal safety was preserved throughout the trial.
Of note, 25 % of women with fetal surgery demon-
strated uterine wall thinning in the hysterotomy area,
10 % had dehiscences. Yet, a uterine rupture did not
occur.
Considering all data generated by the MOMS Trial and
after judicious weighing of benefits against risks, the fol-
lowing conclusions appear correct: although open mater-
nal–fetal surgery for MMC is not completely curative and
not free of risks, it definitely yields the best overall results
achievable today. Therefore, it represents a novel standard
of care that must be taken into consideration when a fetus is
diagnosed with this devastating malformation.
Percutaneous, endoscopic fetal MMC repair:
a problematic approach
Fetal endoscopic interventions have already conquered a
certain position in the field of prenatal medicine, for
instance with regard to laser therapy for twin–twin trans-
fusion syndrome [49] or tracheal plugging in severe cases
Fig. 3 a Before surgery: small
posterior fossa and marked
hindbrain herniation into the
proximal cervical spine (white
arrow). The large cystic MMC
is clearly discernible (asterisk).
b Fetal MRI 4 weeks after fetal
surgery. Hindbrain herniation is
already completely resolved.
c Neonatal MRI at 10 days of
life: There is no hindbrain
herniation and the medulla
oblongata can be seen in
projection on the foramen
occipitale magnum (white
arrow) (this is one of our own
cases)
Fig. 4 Three typical aspects
(own cases) of repair sites on
the first day of life. A perfectly
healed skin, no cerebrospinal
fluid leak, and a suture that is
still in place is what we observe
on a regular basis
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of congenital diaphragmatic hernia [50]. Of note, these
procedures do not involve formal surgical steps like cut-
ting, preparing, resecting, and suturing of tissues, or
meticulous hemostasis, all of which are indispensable for a
neurosurgically correct MMC repair.
In theory, a minimally invasive repair variant looks
attractive, in particular if the well-documented benefits
associated with postnatal endoscopic operations would also
be present in the prenatal setting.
Until present, three centers have reported on their
results with endoscopic surgery (Bruner, Nashville, USA
[32, 51, 52]; Farmer, San Francisco, USA [53]; Kohl,
Giessen–Marburg, formerly Bonn, Germany [54–56]). In
the upshot, some of these patients might have drawn
benefit from the fetal endoscopic intervention, yet patient
numbers are two small [32, 51, 53], or, data are incon-
sistent [54, 55, 57, 58] so that a clean picture regarding
positive effects is difficult to obtain. On the other hand,
these reports provided details on staggering rates of
serious complications, including intraoperative fetal
death, massive trocar site hemorrhage with termination of
a not completed intervention, partial or failed patch
coverage of the lesion so that postnatal repair was man-
datory, technical issues forcing conversion to open sur-
gery, extremely long operations times, oligohydramnios
due to port site leakage, premature rupture of amniotic
membranes, chorioamnionitis, and extreme prematurity
(e.g., 28 weeks mean age at delivery!) [32, 53, 55, 58,
59]. Based on these grim experiences, the two US centers
understandably abandoned the endoscopic approach,
while the center in Giessen–Marburg continues the
program.
Definitely, the multiple port sites represent the main
problem on the maternal side: ports are inserted percuta-
neously into the amniotic cavity (no direct vision!), are
moved around over long hours in an anatomically frail
environment where chorionic and amniotic membranes are
very loosely affixed, thus they are prone to tearing and
bleeding. Finally, these ports are pulled out, again without
direct vision and, crucially, with absolute no means to
control and seal said membranes and no ways to reliably
stop eventual bleeding or amniotic fluid leakage. Thus, the
stage is set for uncontrollable hemorrhage as well as
uncontrollable rupture and separation of membranes.
Consequently, risks are high for amniotic fluid leak, oli-
gohydramnios, uterine wall hematoma, chorioamnionitis,
premature labor, and premature birth. All of these dan-
gerous complications may turn out fatal. Of note, the sta-
pler employed for open hysterotomy warrants, on a very
reliable basis, membrane and muscle layer sealing
throughout the operation.
The main problem on the fetal side is that the endo-
scopic ‘‘repair’’ mainly consists of a simple patch
application over the lesion. Although patch coverage may
provide a certain protection of the neural tissue, it does by
no means come close to the correct and relatively complex
neurosurgical reconstruction. The latter mandates a formal
resection of the zona epithelioserosa, untethering of the
filum terminale, pia mater closure and neural placode
tubularization, watertight dura mater closure, reinforce-
ment of that area with paraspinal (myo) fascial flaps, and,
finally, skin closure. Of note, the cited method is applied
successfully for open fetal repair as well!
Undoubtedly, there is ongoing and harsh controversy
over the above-raised critical issues, exemplified by a
published statement of David Shurtleff, one of the most
renowned spina bifida experts worldwide. In a comment to
a recent article by Verbeek et al. reporting on the outcome
of 13 endoscopically treated patients of the Marburg–Gi-
essen group, he wrote: ‘‘The extremely high complication
rates for mother and infant in this study and the principle of
primum non nocere indicate that at this time it is unethical
to pursue intrauterine endoscopic myelomeningocele repair
Table 1 Recommendation for centers offering fetal surgery for
MMC
1.Experienced fetal care team consisting of:
Functional team, experienced in collaborative patient care with a
designated leader
Care coordinator
Fetal echocardiographer
Fetal surgeon with experience performing hysterotomy and
closure
Genetic counselor
Magnetic resonance imaging equipment and expertise to perform
and interpret fetal cases
Maternal–fetal medicine specialist
Neonatologist
Obstetric anesthesiologist
Pediatric anesthesiologist
Pediatric neurosurgeon
Social worker
Ultrasound equipment and expertise to perform and interpret
fetal cases
2.Multidisciplinary spina bifida program
3.Level IIIC neonatal intensive care unit
4.Labor and delivery unit capable of caring for perioperative
complications and obstetric emergencies with around the clock
availability of maternal–fetal medicine (MFM) specialists/
obstetricians skilled in managing delivery of patients with a
recent hysterotomy
5.Institutional review board
6.Ethics committee
7.Maternal/fetal advocate to ensure that counseling is nondirective
8.Institutional commitment to track long-term pediatric
neurodevelopment outcomes
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in humans until the procedure has been perfected in ani-
mals’’ [60].
In terms of a general consideration, it appears logical
that any alternative approach or program must deliver
similar or better results than the evidence-based benchmark
of the MOMS Trial to be medically and ethically
justifiable.
The post-MOMS era deserves pondered and sensible
reflection
Landmark publications like the MOMS Trial in ‘‘The New
England Journal of Medicine’’ tend to produce a hype. An
advantage may be that the innovation rapidly gains broad
perception, acceptance and, in the best case scenario, a
successful global spawn. A downside may be that bad
results produced by adventurous yet unqualified pseudo-
experts jeopardise the newborn novelty.
The authors of this review applaud the fact that in
February 2014, a position paper appeared in the American
Journal of Obstetrics and Gynecology, authored by a newly
composed expert group from all involved disciplines, i.e.,
the ‘‘MMC Maternal–Fetal Management Task Force’’ [61].
This article outlines a framework of minimal prerequisites
(Table 1) that must be fulfilled for a center to offer prenatal
treatment for MMC. Even though such an initiative does,
needless to say, not have legal power, it may develop the
power of a generally accepted and publicly known (Inter-
net!) codex of conduct risky not to comply with. The
worldwide community of experts in the field of fetal
diagnosis and therapy has, now!, the unique chance to set
forth rigorous rules and regulations to define and certify
centers allowed to offer fetal surgery for MMC.
The world map today
In light of the above allocation considerations, it is man-
datory to have a look at the status quo. To the best of our
knowledge, a total of 7 centers are offering fetal surgery for
spina bifida in the US: Apart from the three MOMS Trial
Centers, there is Cincinnati, Houston (two programs,
competing across the street, sic!) [62], and Denver. In
South America, there is a center in Sao Paolo, Brasil, with
remarkable experience and several clinical publications
[63–65]. All other programs seem to be located in Europe.
The ones who have reported on their results in peer-
reviewed articles are in Katowice, Poland [66] and Zurich,
Switzerland [67–69]. Our program was started in Decem-
ber 2010 when the MOMS Trial was stopped. We have
treated thirteen cases so far and, overall, our preliminary
results are in line with those of the MOMS Trial
(manuscript in preparation). Finally, there is a program in
Barcelona, Spain, and one in Leuven, Belgium (no clinical
publications).
Future homework and responsibilities
There are a number of issues that must be addressed by
those performing fetal surgery for MMC. Clearly, long-
term follow-up studies are a must to check whether results
are durable. The as of yet immature endoscopic approach
must be freed from its currently prohibitive quandaries.
Engineering fetal dura mater and fetal skin equivalents
could facilitate the operation and improve results. Other
tissue engineering strategies like the ones suggested by
Flake [70, 71] or molecular biology-based approaches
might eventually originate entirely new, non-surgical
therapies.
After all, and again, these rare, complex, and extremely
challenging cases must be treated in a few really qualified
high-volume centers. Undeniably, case load dilution jeop-
ardises outcome and is therefore against the best interest of
the courageous expectant mother and her unborn child.
Conclusions
Although the MOMS Trial has generated an unparalleled
quality of evidence in favor of open fetal surgery, there are
three relevant reservations: maternal–fetal surgery is not a
cure, it is not devoid of risks for both mother and fetus, and
there is not yet proof of durable, ideally life-long, benefit.
Nevertheless, prenatal repair is the novel standard of care
and must be offered to those women who are eligible and
determined to offer their yet to be born child the best
chance there is today.
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